Apomorphine

證據等級: L5

預測適應症: 10 個

Apomorphine: From Parkinson’s Disease to Schizophrenia

One-Sentence Summary

Apomorphine is a non-selective dopamine receptor agonist, primarily known internationally for treating motor fluctuations in advanced Parkinson’s disease, though it is not currently registered in Australia. The TxGNN model predicts it may be effective for Schizophrenia — ranked 5th overall, and the most evidenced prediction among the top 10 (the four higher-ranked predictions are all rare neurological conditions with no supporting clinical evidence). This prediction is supported by 2 clinical trials and 20 publications, though the evidence is exploratory in nature and historically mixed.

Quick Overview

Item	Content
Original Indication	Parkinson’s disease — motor fluctuations (not registered in Australia; internationally established)
Predicted New Indication	Schizophrenia
TxGNN Prediction Score	99.69%
Evidence Level	L3
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Note on prediction selection: TxGNN’s top-ranked prediction (polymicrogyria with cerebellar hypoplasia, score 99.75%) and predictions at ranks 2–4 are all rated L5 with no clinical trials or relevant literature, and no known pharmacological link. Schizophrenia (rank 5, score 99.69%) is the first prediction with meaningful clinical evidence and a mechanistic rationale, and is therefore the focus of this report.

Why is This Prediction Reasonable?

Apomorphine is a non-selective dopamine receptor agonist with activity at D1, D2, D3, and D4 receptors. Internationally, it is best established for the acute rescue of “off” episodes in advanced Parkinson’s disease, where it bypasses the oral route and mimics endogenous dopamine to restore motor function. Detailed mechanism of action data is not available in the current evidence pack; based on published pharmacology, its primary mode of action is direct dopamine receptor stimulation.

The theoretical basis for this prediction rests on the dopamine hypothesis of schizophrenia, which implicates mesolimbic hyperdopaminergia in the generation of positive symptoms (hallucinations and delusions). At low doses, Apomorphine preferentially stimulates presynaptic D2 autoreceptors — inhibitory feedback receptors that suppress dopamine synthesis and release — which could theoretically dampen dopaminergic overactivity and reduce positive symptoms. This presynaptic selectivity at low doses is the pharmacological rationale explored in decades of research.

However, this prediction carries a well-recognised mechanistic dilemma. At higher doses, Apomorphine stimulates postsynaptic dopamine receptors and may worsen psychotic symptoms. This dose-dependent bidirectional effect creates an extremely narrow therapeutic window that has proved very difficult to exploit clinically. As a result, Apomorphine has been used almost exclusively as a pharmacological challenge probe to characterise dopaminergic dysfunction in schizophrenia research, rather than as a treatment agent. Clinical studies from the 1970s through to the early 2000s yielded largely mixed and non-significant findings for symptom improvement.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT03911726	NA	Active, Not Recruiting	140	PET/MRI mechanistic study examining whether long-term antipsychotic treatment causes dopamine receptor supersensitivity in patients with schizophrenia. Apomorphine is used as a diagnostic dopamine challenge probe to assess receptor sensitivity — not as a therapeutic intervention. Provides pharmacological context but no efficacy data.
NCT00009048	Phase 2	Completed	30	Investigation of serotonergic agent EMD 128130 for Parkinson’s disease and levodopa-induced dyskinesias. Apomorphine used as standard-of-care background therapy. Not a schizophrenia treatment trial; provides safety and tolerability reference data only.

Neither trial represents a therapeutic trial of Apomorphine for schizophrenia. Both are mechanistic or background-treatment studies that support pharmacological plausibility but provide no efficacy evidence for this indication.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
11394190	2001	Review	J Psychiatry Neurosci	Comprehensive review concluding that Apomorphine — despite being a DA agonist — does not reliably induce psychosis in healthy subjects or exacerbate schizophrenia at doses stimulating postsynaptic receptors. Directly challenges a key prediction of the dopamine hypothesis and highlights the clinical paradox.
6372737	1984	Clinical Study	Arch Gen Psychiatry	Double-blind, placebo-controlled study in 25 male schizophrenic inpatients; low-dose Apomorphine (0.75 mg SC) produced no significant improvement or deterioration in psychotic or tardive dyskinetic symptoms versus placebo. Concomitant prolactin and growth hormone measures reported.
6682989	1983	Clinical Study	Prog Neuropsychopharmacol Biol Psychiatry	Double-blind study of low-dose Apomorphine (0.01 mg/kg) in 12 chronic schizophrenic patients. No significant overall therapeutic effect versus placebo. Anxiety and depression subscales showed some improvement. CT-defined subgroups showed differing responses, suggesting possible patient-selection effects.
1099172	1975	Clinical Study	J Neurol Neurosurg Psychiatry	Double-blind, placebo-controlled trial in 40 men (predominantly alcoholics); Apomorphine HCl 1 mg SC three times daily for 14 days. No schizophrenic symptoms induced and no significant difference from placebo on the Hamilton, Zung, or Brief Psychiatric Rating Scales.
12727131	2003	Clinical Study	Psychoneuroendocrinology	Prolactin, ACTH and cortisol responses to Apomorphine challenge in 20 untreated schizophrenia inpatients versus 23 healthy controls. Different patterns of dopaminergic and serotonergic responsiveness were associated with distinct schizophrenic symptom clusters.
8824341	1996	Clinical Neuroimaging	J Neurosci	PET study in unmedicated schizophrenic patients and healthy controls during a verbal fluency task; Apomorphine modulated fronto-temporal dopaminergic circuitry differently in schizophrenia versus controls, providing neuroimaging evidence of aberrant prefrontal dopamine function.
540209	1979	Clinical Study	Br J Psychiatry	Characterisation of growth hormone and prolactin responses to Apomorphine challenge; acute schizophrenics show exaggerated GH responses, suggesting dopaminergic hypersensitivity — though chronic patients show blunted responses. Supports heterogeneity within schizophrenia.
6718635	1984	Clinical Study	Psychopharmacol Bull	Dedicated clinical investigation of Apomorphine’s effects in schizophrenia; provides foundational exploratory clinical data on the drug–disease relationship.
7025187	1981	Review	Schizophr Bull	Review of the dopamine receptor supersensitivity hypothesis in schizophrenia; Apomorphine challenge data used to assess receptor sensitivity states across illness phases.
2573101	1989	Review	Psychiatr J Univ Ottawa	Review of dopaminergic agonists in schizophrenia; discusses the bidirectional effects of Apomorphine at presynaptic versus postsynaptic receptors and implications for the D1/D2 receptor model.

Australia Market Information

Apomorphine is not currently listed on the Australian Register of Therapeutic Goods (ARTG). There are no TGA-approved products containing this drug registered in Australia at the time of this report (data cutoff: 5 April 2026).

Healthcare professionals seeking to use Apomorphine in Australia for any indication would need to access it via the TGA’s Special Access Scheme (SAS) or through the Authorised Prescriber pathway. Standard ARTG regulatory pathway would be required for any commercial repurposing application.

Safety Considerations

Safety data for this drug is not available in the current evidence pack for the Australian context.

Please refer to the TGA-approved Product Information (PI) — or, in the absence of an Australian PI, international product monographs such as the UK/EU Summary of Product Characteristics (SmPC) for APO-go® or equivalent — for full information on warnings, contraindications, and drug interactions prior to any clinical use or evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score (99.69%) and L3-level evidence from historical clinical studies, the evidence for Apomorphine as a therapeutic agent in schizophrenia is weak and contradictory — its predominant role in the schizophrenia literature has been as a pharmacological research probe (dopamine challenge test), not a treatment. The dose-dependent bidirectional effect on presynaptic versus postsynaptic dopamine receptors creates a prohibitively narrow therapeutic window, and multiple small controlled trials in the 1975–1984 period found no significant clinical benefit over placebo.

To proceed with further evaluation, the following is needed:

MOA data: Retrieve full DrugBank entry (DB00714) to formally document receptor binding profile and pharmacodynamic properties
Safety baseline: Obtain an international PI or SmPC (e.g., APO-go® UK SmPC) to complete the S1 safety screening, including contraindications, key warnings, and drug–drug interactions
Formulation review: Assess whether any newer Apomorphine formulations (e.g., sublingual film Kynmobi® approved in the USA) or delivery routes offer improved presynaptic selectivity at low doses, potentially widening the therapeutic window
Contemporary evidence scan: Search post-2005 literature for any controlled trials exploring Apomorphine or selective presynaptic D2 agonists specifically in schizophrenia or dopamine supersensitivity psychosis
Clinical context assessment: Evaluate whether Apomorphine repurposing offers any meaningful advantage over currently available antipsychotic agents, given the mature treatment landscape for schizophrenia in Australia

This report is for research purposes only and does not constitute medical advice. All repurposing candidates require clinical validation before therapeutic application. This document should be read in conjunction with current TGA-approved prescribing information and clinical guidelines.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.